The World Health Organization (WHO) has approved the emergency use of a novel coronavirus vaccine jointly developed by the multinational pharmaceutical company AstraZeneca and the University of Oxford in the UK.
Tedros Adhanom Gebrejesus, Secretary General of the World Health Organization (WHO), made a statement yesterday (15th) at a press conference at the WHO headquarters in Geneva, Switzerland.
Secretary General Gebreyesus explained that the approved vaccine will be produced by SK Bio in Korea and Serum Research Institute in India, and will be supplied through the international vaccine cooperation program, COVAX Facility. I did.
AstraZeneca made a statement today and said that in the first half of this year, more than 300 million doses of vaccine will be supplied to 145 countries through the COVAX program.
Meanwhile, the WHO refuted that “there is no evidence that there is a significant change in vaccine efficacy” regarding South Africa’s cessation of the AstraZeneca vaccine, raising concerns about its efficacy against the mutant virus.
Earlier, the WHO Immunization Strategy Advisory Group (SAGE) recommended vaccination for the age group over 18, saying that the AstraZeneca vaccine is estimated to be effective at 63.09% on the 8th.
WHO’s approval of the vaccine is the second time after the Pfizer vaccine last December.
VOA news
–
–
/cloudfront-us-east-1.images.arcpublishing.com/eluniverso/AQV2UPVRJ5BYJFOFGB47UAADDM.jpg "New York is experiencing a digital ‘fashion week’ | Social Networks | Entertainment")
